The BTK inhibitor ibrutinib is well known as a treatment option in chronic lymphocytic leukemia and mantle cell lymphoma, in which ibrutinib silences the downstream pathways of ERK, PI3K, NF-κB and Akt, and induces apoptosis of malignant B cells [40, 41]. The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.